NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [12/30/2025 14:55 PST] NeuroSense Therapeutics Ltd. (NASDAQ:NRSN), Down By 100% ($0.85) From $0.85 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [12/17/2025 07:02 PST] NRSN Expected to Trade Down After Bearish Patterns Develop
• [11/18/2025 14:36 PST] NeuroSense Therapeutics Ltd. (NASDAQ:NRSN), Up By 100% ($1.04) From $1.04 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/18/2025 07:03 PST] NRSN Expected to Trade Up After Bullish Patterns Develop
• [11/11/2025 07:03 PST] NRSN Expected to Trade Down After Bearish Patterns Develop